17β-estradiol protects against doxorubicin-induced cardiotoxicity in male Sprague-Dawley rats by regulating NADPH oxidase and apoptosis genes

Zhang,Xiao‑Juan; Cao,Xiao‑Qing; Zhang,Chun‑Sheng; Zhao,Zhuo

doi:10.3892/mmr.2017.6332

17β-estradiol protects against doxorubicin-induced cardiotoxicity in male Sprague-Dawley rats by regulating NADPH oxidase and apoptosis genes

Authors:
- Xiao‑Juan Zhang
- Xiao‑Qing Cao
- Chun‑Sheng Zhang
- Zhuo Zhao
View Affiliations

Affiliations: Department of Cardiology, Shandong Provincial Chest Hospital, Jinan, Shandong 250013, P.R. China, Department of Cardiology, Jinan Central Hospital Affiliated with Shandong University, Jinan, Shandong 250013, P.R. China
Published online on: March 16, 2017 https://doi.org/10.3892/mmr.2017.6332
Pages: 2695-2702

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Doxorubicin (DOX) is one of the most effective chemotherapeutic agents for the treatment of a number of malignancies. However, its use is limited by serious cardiotoxic effects, for which there are currently no reliable pharmacologic therapies. Estrogen has exhibited protective effects against cardiac stressors in male and female animal models; however, its effects on DOX‑induced cardiotoxicity remain unknown. High mortality and morbidity rates have been observed in patients with cancer worldwide, and DOX is often administered to a greater number of men than women. Therefore, the present study employed male Sprague-Dawley rats to evaluate the protective effects of 17β-estradiol (E2) against DOX-induced cardiotoxicity. A total of 4 mg/kg DOX was administered to 14‑week‑old male Sprague‑Dawley rats by intraperitoneal injection twice a week for 2 weeks. At 3 weeks following the first injection of DOX, an echocardiographic study revealed that DOX administration significantly decreased cardiac ejection fraction and fractional shortening by 20 and 29%, respectively, when compared with the vehicle‑treated control rats (P<0.05). This was associated with decreased heart weight, myofibrillar disorganization and myofiber loss. The serum biomarkers for heart injury, including alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase and creatine kinase, were increased in DOX vs. vehicle‑treated rats (P<0.05). E2 treatment by a daily subcutaneous injection of 2 mg/kg body weight attenuated the cardiotoxic effects of DOX. In addition, E2 treatment inhibited the DOX‑induced increase in the expression of cardiac genes, nicotinamide adenine dinucleotide phosphate oxidase (NOX) 2, NOX4, B‑cell lymphoma 2‑associated X protein and caspase 3. These results demonstrate that E2 treatment may protect the heart against DOX-induced cardiotoxicity in male rats potentially through the regulation of NOX2, NOX4 and apoptosis genes.

View Figures

View References

1	Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS and Younes A: Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: A 10-year follow-up study. Leuk Lymphoma. 53:801–806. 2012. View Article : Google Scholar : PubMed/NCBI
2	Ogilvie CM, Crawford EA, Slotcavage RL, King JJ, Lackman RD, Hartner L and Staddon AP: Treatment of adult rhabdomyosarcoma. Am J Clin Oncol. 33:128–131. 2010.PubMed/NCBI
3	Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA and Oliveira PJ: Doxorubicin-induced cardiotoxicity: From bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 34:106–135. 2014. View Article : Google Scholar : PubMed/NCBI
4	Shi Y, Moon M, Dawood S, McManus B and Liu PP: Mechanisms and management of doxorubicin cardiotoxicity. Herz. 36:296–305. 2011. View Article : Google Scholar : PubMed/NCBI
5	Langer SW: Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res. 6:357–363. 2014. View Article : Google Scholar : PubMed/NCBI
6	Molix L: Sex differences in cardiovascular health: Does sexism influence women's health? Am J Med Sci. 348:153–155. 2014. View Article : Google Scholar : PubMed/NCBI
7	Brower GL, Gardner JD and Janicki JS: Gender mediated cardiac protection from adverse ventricular remodeling is abolished by ovariectomy. Mol Cell Biochem. 251:89–95. 2003. View Article : Google Scholar : PubMed/NCBI
8	Xu Y, Arenas IA, Armstrong SJ and Davidge ST: Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc Res. 57:388–394. 2003. View Article : Google Scholar : PubMed/NCBI
9	Van Eickels M, Grohé C, Cleutjens JP, Janssen BJ, Wellens HJ and Doevendans PA: 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation. 104:1419–1423. 2001. View Article : Google Scholar : PubMed/NCBI
10	Nelson LR and Bulun SE: Estrogen production and action. J Am Acad Dermatol. 45:(3 Suppl). S116–S124. 2001. View Article : Google Scholar : PubMed/NCBI
11	Ropero AB, Eghbali M, Minosyan TY, Tang G, Toro L and Stefani E: Heart estrogen receptor alpha: Distinct membrane and nuclear distribution patterns and regulation by estrogen. J Mol Cell Cardiol. 41:496–510. 2006. View Article : Google Scholar : PubMed/NCBI
12	Murphy E: Estrogen signaling and cardiovascular disease. Circ Res. 109:687–696. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kunnas TA, Laippala P, Penttilä A, Lehtimäki T and Karhunen PJ: Association of polymorphism of human alpha oestrogen receptor gene with coronary artery disease in men: A necropsy study. BMJ. 321:273–274. 2000. View Article : Google Scholar : PubMed/NCBI
14	Jankowska EA, Rozentryt P, Ponikowska B, Hartmann O, Kustrzycka-Kratochwil D, Reczuch K, Nowak J, Borodulin-Nadzieja L, Polonski L, Banasiak W, et al: Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 301:1892–1901. 2009. View Article : Google Scholar : PubMed/NCBI
15	Kadokami T, McTiernan CF, Higuichi Y, Frye CS, Kubota T and Feldman AM: 17 Beta-estradiol improves survival in male mice with cardiomyopathy induced by cardiac-specific tumor necrosis factor-alpha overexpression. J Interferon Cytokine Res. 25:254–260. 2005. View Article : Google Scholar : PubMed/NCBI
16	Cook MB, McGlynn KA, Devesa SS, Freedman ND and Anderson WF: Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev. 20:1629–1637. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wang H, Da Silva J, Alencar A, Zapata-Sudo G, Lin MR, Sun X, Ahmad S, Ferrario CM and Groban L: Mast cell inhibition attenuates cardiac remodeling and diastolic dysfunction in middle-aged, ovariectomized Fischer344 × Brown Norway rats. J Cardiovasc Pharmacol. 68:49–57. 2016. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Blenck CL, Harvey PA, Reckelhoff JF and Leinwand LA: The importance of biological sex and estrogen in rodent models of cardiovascular health and disease. Circ Res. 118:1294–1312. 2016. View Article : Google Scholar : PubMed/NCBI
20	Knowlton AA and Korzick DH: Estrogen and the female heart. Mol Cell Endocrinol. 389:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
21	Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellström D and Ohlsson C: Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab. 94:2482–2488. 2009. View Article : Google Scholar : PubMed/NCBI
22	Balakrishnan B, Chiplunkar SV and Indap MM: Methanol extract of euchelus asper prevents bone resorption in ovariectomised mice model. J Osteoporos. 2014:3481892014. View Article : Google Scholar : PubMed/NCBI
23	Shi M, Ma L, Zhou L and Fu P: Renal protective effects of 17β-estradiol on mice with acute aristolochic acid nephropathy. Molecules. 21:pii: E1391. 2016. View Article : Google Scholar
24	Ghosh J, Das J, Manna P and Sil PC: The protective role of arjunolic acid against doxorubicin induced intracellular ROS dependent JNK-p38 and p53-mediated cardiac apoptosis. Biomaterials. 32:4857–4866. 2011. View Article : Google Scholar : PubMed/NCBI
25	Han XZ, Gao S, Cheng YN, Sun YZ, Liu W, Tang LL and Ren DM: Protective effect of naringenin-7-O-glucoside against oxidative stress induced by doxorubicin in H9c2 cardiomyocytes. Biosci Trends. 6:19–25. 2012.PubMed/NCBI
26	Ichihara S, Yamada Y, Kawai Y, Osawa T, Furuhashi K, Duan Z and Ichihara G: Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity. Biochem Biophys Res Commun. 359:27–33. 2007. View Article : Google Scholar : PubMed/NCBI
27	Mut-Salud N, Álvarez PJ, Garrido JM, Carrasco E, Aránega A and Rodríguez-Serrano F: Antioxidant intake and antitumor therapy: Toward nutritional recommendations for optimal results. Oxid Med Cell Longev. 2016:67195342016. View Article : Google Scholar : PubMed/NCBI
28	Bao MH, Dai W, Li YJ and Hu CP: Rutaecarpine prevents hypoxia-reoxygenation-induced myocardial cell apoptosis via inhibition of NADPH oxidases. Can J Physiol Pharmacol. 89:177–186. 2011. View Article : Google Scholar : PubMed/NCBI
29	Zhang YS, He L, Liu B, Li NS, Luo XJ, Hu CP, Ma QL, Zhang GG, Li YJ and Peng J: A novel pathway of NADPH oxidase/vascular peroxidase 1 in mediating oxidative injury following ischemia-reperfusion. Basic Res Cardiol. 107:2662012. View Article : Google Scholar : PubMed/NCBI
30	Nabeebaccus A, Zhang M and Shah AM: NADPH oxidases and cardiac remodelling. Heart Fail Rev. 16:5–12. 2011. View Article : Google Scholar : PubMed/NCBI
31	Gilleron M, Marechal X, Montaigne D, Franczak J, Neviere R and Lancel S: NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun. 388:727–731. 2009. View Article : Google Scholar : PubMed/NCBI
32	Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, Shah AM, McDermott BJ and Grieve DJ: Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res. 70:9287–9297. 2010. View Article : Google Scholar : PubMed/NCBI
33	Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, Fabbi P, Ballestrero A, Brunelli C and Barsotti A: Matrix metalloproteinase-2 and −9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res. 69:736–745. 2006. View Article : Google Scholar : PubMed/NCBI
34	Siwik DA, Pagano PJ and Colucci WS: Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol. 280:C53–C60. 2001.PubMed/NCBI
35	Grieve DJ, Byrne JA, Siva A, Layland J, Johar S, Cave AC and Shah AM: Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. J Am Coll Cardiol. 47:817–826. 2006. View Article : Google Scholar : PubMed/NCBI
36	Sumi D, Hayashi T, Matsui-Hirai H, Jacobs AT, Ignarro LJ and Iguchi A: 17beta-estradiol inhibits NADPH oxidase activity through the regulation of p47phox mRNA and protein expression in THP-1 cells. Biochim Biophys Acta. 1640:113–118. 2003. View Article : Google Scholar : PubMed/NCBI
37	Miller AA, Drummond GR, Mast AE, Schmidt HH and Sobey CG: Effect of gender on NADPH-oxidase activity, expression, and function in the cerebral circulation: Role of estrogen. Stroke. 38:2142–2149. 2007. View Article : Google Scholar : PubMed/NCBI
38	Zhang QG, Raz L, Wang R, Han D, De Sevilla L, Yang F, Vadlamudi RK and Brann DW: Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. J Neurosci. 29:13823–13836. 2009. View Article : Google Scholar : PubMed/NCBI
39	Hosseinzadeh L, Behravan J, Mosaffa F, Bahrami G, Bahrami A and Karimi G: Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. Food Chem Toxicol. 49:1102–1109. 2011. View Article : Google Scholar : PubMed/NCBI
40	Kazama K, Okada M and Yamawaki H: Adipocytokine, omentin inhibits doxorubicin-induced H9c2 cardiomyoblasts apoptosis through the inhibition of mitochondrial reactive oxygen species. Biochem Biophys Res Commun. 457:602–607. 2015. View Article : Google Scholar : PubMed/NCBI
41	Claycomb WC and Palazzo MC: Culture of the terminally differentiated adult cardiac muscle cell: A light and scanning electron microscope study. Dev Biol. 80:466–482. 1980. View Article : Google Scholar : PubMed/NCBI